IKT: Inhibikase Therapeutics, Inc. Stock

SIC 2836 – Biological Products, Except Diagnostic Substances (Biotech)

Valuation
Market Cap ($M) 155.21
Enterprise Value ($M) 154.37
Book Value ($M) -0.53
Book Value / Share -0.01
Price / Book -292.53
NCAV ($M) -0.72
NCAV / Share -0.01
Price / NCAV -216.37

Profitability (mra)
Return on Invested Capital (ROIC) n/a
Return on Assets (ROA) -1.09
Return on Equity (ROE) -1.30

Liquidity (mrq)
Quick Ratio 0.85
Current Ratio 0.85

Balance Sheet (mrq) ($M)
Current Assets 4.19
Assets 4.38
Liabilities 4.91
Debt n/a
Equity n/a

Income Statement (mra) ($M)
Revenue 0.00
Operating Income 0.00
Net Income 0.00

Cash Flow Statement (mra) ($M)
Cash From Operations 0.00
Cash from Investing 0.00
Cash from Financing 0.00

(click for more detail)

File Date Form Activist 13D/G Investors Ownership
(%)
Change
(%)
11-14 13G Armistice Capital, Llc 9.99
10-28 13G Soleus Private Equity Fund III, L.P. 9.99
10-28 13G SP IKT Holdings LLC 8.69
10-25 13G Sands Capital Life Sciences Pulse Fund II, L.P. 16.30
10-22 13G Perceptive Advisors Llc 9.99
10-17 13G Fairmount Funds Management LLC 9.90
10-17 13G Commodore Capital Lp 9.99
10-10 13G Point72 Asset Management, L.P. 8.40

Top 13F Investors Shares
(1000)
Change
(%)
Value
($1000)
Change
(%)

(click for more detail)

Date Insider Trades Code Shares Value

(click for more detail)

File Date Form SEC Filings
2024-11-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-08-14 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-05-15 10-Q UNITED STATES SECURITIES AND EXCHANGE COMMISSION WASHINGTON, DC 20549 FORM 10-Q
2024-03-27 10-K UNITED STATES SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549 FORM 10-K

(click for more detail)
Short Volume
Market Date Short Volume Total Volume Short Volume Ratio
2024-11-25 54,410 164,432 33.09
2024-11-22 47,849 189,534 25.25
2024-11-21 49,308 250,000 19.72
2024-11-20 12,251 115,616 10.60

(click for more detail)

Similar Companies
HOTH – Hoth Therapeutics, Inc. HRTX – Heron Therapeutics, Inc.
ICCC – ImmuCell Corporation IMCC – IM Cannabis Corp.
IMMX – Immix Biopharma, Inc.


Financial data and stock pages provided by
Fintel.io



This entry was posted in . Bookmark the permalink.